Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials
Open Access
Abstract
Despite tremendous efforts in basic research and a growing number of clinical trials aiming to find effective treatments, amyotrophic lateral sclerosis (ALS) remains an incurable disease. One possible reason for the lack of effective causative treatment options is that ALS may not be a single disease entity but rather may represent a clinical syndrome, with diverse genetic and molecular causes, histopathological alterations, and subsequent clinical presentations contributing to its complexity and variability among individuals. Defining a way to subcluster ALS patients is becoming a central endeavor in the field. Identifying specific clusters and applying them in clinical trials could enable the development of more effective treatments. This review aims to summarize the available data on heterogeneity in ALS with regard to various aspects, e.g., clinical, genetic, and molecular.Keywords
Funding Information
- EU Joint Programme—Neurodegenerative Disease Research (JPND) (BMBF 01ED2204A)
- Clinician Scientist Program of the Centre for Transdisciplinary Neurosciences Rostock (CTNR) of the University Medical Center Rostock (BMBF 01ED2204A)
This publication has 153 references indexed in Scilit:
- Proteomics and mathematical modeling of longitudinal CSF differentiates fast versus slow ALS progressionAnnals of Clinical and Translational Neurology, 2023
- Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblastsAnnals of Clinical and Translational Neurology, 2022
- C‐reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic reviewBrain and Behavior, 2022
- CSF chitinases before and after symptom onset in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2020
- Spreading in ALS: The relative impact of upper and lower motor neuron involvementAnnals of Clinical and Translational Neurology, 2020
- Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral SclerosisAnnals of Neurology, 2019
- Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral SclerosisJAMA Neurology, 2017
- Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and CreatinineJAMA Neurology, 2014
- Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survivalEMBO Molecular Medicine, 2012
- Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutationsAnnals of Neurology, 2007